Affinity Asset Advisors »

Monopar Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Monopar Therapeutics (MNPR) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Monopar Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Monopar Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Monopar Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $6.5M 80k 81.67
2025-06-30 $2.4M 68k 35.78
2025-03-31 $2.3M 62k 36.41

More positions owned by Affinity Asset Advisors

Insmed Com Par $.01 (INSM)
Verona Pharma Sponsored Ads (VRNA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Apogee Therapeutics (APGE)
Arcellx Common Stock (ACLX)
Alkermes SHS (ALKS)
Nuvalent Inc-a (NUVL)
Abivax Sa Sponsored Ads (ABVX)
Mineralys Therapeutics (MLYS)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Merus N V (MRUS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Lexeo Therapeutics (LXEO)

View all positions for Affinity Asset Advisors

Top funds holding Monopar Therapeutics

Henderson Group
Adage Capital Partners GP
RA Capital Management
Wellington Management Company
Vanguard Group
BlackRock
Deerfield Management Company
Saturn V Capital Management
TCG Crossover Management
ADAR1 Capital Management
Vivo Capital
Geode Capital Management
Affinity Asset Advisors
State Street Corporation
Driehaus Capital Management

View all funds holding Monopar Therapeutics